- Home
- NRIX vs OLMA Comparison
NRIX vs OLMA Comparison
Compare NRIX & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | OLMA |
|---|---|---|
| Founded | 2009 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NRIX | OLMA |
|---|---|---|
| Price | $15.88 | $24.28 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 8 |
| Target Price | $29.46 | ★ $42.00 |
| AVG Volume (30 Days) | 844.9K | ★ 1.3M |
| Earning Date | 05-01-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,987,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 99.31 | N/A |
| 52 Week Low | $8.18 | $2.86 |
| 52 Week High | $22.50 | $36.26 |
Technical Indicators
Market Signals| Indicator | NRIX | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 47.40 |
| Support Level | $15.62 | $22.97 |
| Resistance Level | $19.98 | $27.38 |
| Average True Range (ATR) | 0.78 | 1.46 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 36.46 | 44.34 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.